› Forums › General Melanoma Community › Keytruda builds its melanoma case
- This topic has 7 replies, 6 voices, and was last updated 6 years ago by kst.
- Post
-
- April 17, 2018 at 10:44 am
- Replies
-
-
- April 17, 2018 at 3:57 pm
The link didn’t link.
-
- April 17, 2018 at 4:58 pm
-
- April 18, 2018 at 7:58 am
complicated issue…
I am pd1 negative so keytruda will not work for me however they told me that Opdivo can work…
difficult to understand…..
-
- April 18, 2018 at 11:39 am
Hi Obtu.bt, it can be confusing but the use of Pd-L1 + or – with melanoma never became a standard because of the clinical trials that showed that anyone witrh melanoma can respond to Immunotherapy. Now they did do staining in the trials and melanoma patients with higher Pd-L1 + staining did do better than those with lower amounts but the Melanoma oncology field decided that it was not a good enough biomarker to be accurate, so when the drugs were approved (Nivo and pembro) there were no specific biomarker criteria. To make things even more cloudy Merck and BMS use different assays to evaluate what Pd-L1+ is and they also used different cut off points (%) that they consider to be positive. All you have to do is look at the Pembro (Keytruda) phase 3 news reports this week showing pembro showed improvement over placebo for stage 3a,b,c melanoma patients. If you read the report you will see that it talks about Pd-L1+ patients and how they did better than Pd-L1- patients. Here are two links, one from Dr. Weber talking about adjuvant melanoma from just before Merck published their findings and a second one about the approval of Nivo a few months back so you can compare the data to the Merck study in the above link. http://www.cancernetwork.com/melanoma/adjuvant-immunotherapy-advanced-melanoma?elq_cid=11002&elq_mid=776&rememberme=1 https://www.onclive.com/web-exclusives/fda-approves-adjuvant-nivolumab-for-melanoma
-
- April 18, 2018 at 4:53 pm
Also, I'm sure I read somewhere that BMS took Merck to court for patent infringement related to Keytruda/Opdivo and won a settlement, as far as I'm aware no direct clinical comparision has ever been done and probably never will
-
- April 18, 2018 at 5:24 pm
-
- April 29, 2018 at 8:36 pm
PV-10 feauturing TexMelanomex
-
- You must be logged in to reply to this topic.